A recent study indicates that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who stop conventional diet and exercise regimens.
Findings released in a leading health publication points out that while obese people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People purchasing these drugs need to be aware of the risk of rapid rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain means a return to original mass within about 18 months.
Comparing Approaches
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Researchers point out that people who lose weight through diet and exercise typically experience a less rapid weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts propose the mode of action of the jabs accounts for the accelerated regain.
These medications imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement results in hunger is uncontrolled, making excessive eating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts argue that, given the significant potential of weight regain, the therapy should be considered ongoing.
This opinion is supported by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Experiences
People who have discontinued the medication report a powerful return of hunger.
"It was like a switch flipping and I was suddenly ravenous," described an individual.
The struggle is compounded if patients have not established lasting lifestyle or habit modifications during therapy.
Widespread Interest
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic solution and lasting health benefits hinges on integrated lifestyle support.
